Hemorrhages during pregnancy, immediate postpartum and late puerperium are complications that bring morbidity and mortality to the patient and the fetus. There is no universal definition of obstetric hemorrhage, because it has not been clearly established, which constitutes excessive blood loss. Loss of blood volume at a rate greater than 150 ml / min (which in 20 minutes would cause the loss of 50% of the volume), which can occur during the gravid or puerperal state, which exceeds 500 ml, postpartum or 1000 ml post Caesarean section. Tranexamic acid is a derivative of lysine used as hemostatic thanks to its antifibrinolytic properties. It inhibits plasminogen activation by blocking the lysine ligands of this molecule. It exerts its antifibrinolytic effect by reversing and competitive blocking of lysine receptors in PLG molecules, preventing its binding to fibrin. Reduces the activation of PLG to PL which inhibits fibrin degradation, thus favoring secondary hemostasis. Tranexamic acid does not show evidence of teratogenicity or other side effects in both the mother and the fetus, epidemiologically proving that there would be no contraindication for use during pregnancy in case of bleeding. Regarding the safety of its use for both the mother and the newborn, clinical trials do not report serious and significant adverse events for the use of tranexamic acid; highlighting evidence indicating mild adverse events with statistical significance in transient discomfort such as headache nausea, vomiting, diarrhea and photopsies. The methodology used is descriptive, with a documentary approach that is, reviewing sources available on the web, such as google scholar, with timely and relevant content from the scientific and updated point of view that enriches the analysis of the topic raised in this article.